Immuneering (IMRX) EBITDA (2020 - 2026)

Immuneering's EBITDA history runs 7 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 8.39% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$54.7 million (up 11.48% YoY), while the FY2025 annual figure was -$55.9 million, up 8.34% from the prior year.
• EBITDA was -$13.8 million for Q1 2026 at Immuneering, down from -$11.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$11.5 million in Q4 2025 to a low of -$18.1 million in Q4 2024.
• Historically, EBITDA has averaged -$13.8 million across 5 years, with a median of -$13.8 million in 2026.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 108.92% in 2022, then jumped 36.33% in 2025.
• A 5-year view of EBITDA shows it stood at -$13.1 million in 2022, then fell by 14.9% to -$15.1 million in 2023, then slipped by 19.68% to -$18.1 million in 2024, then surged by 36.33% to -$11.5 million in 2025, then declined by 19.87% to -$13.8 million in 2026.
• The last three EBITDA figures came in at -$13.8 million (Q1 2026), -$11.5 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.